CRISPR Therapeutics AG (CRSP) EV to FCF (2016 - 2026)

CRISPR Therapeutics AG has disclosed EV to FCF across 11 years of filings, most recently posting 34.55 for Q2 2026.

• In Q2 2026, EV to FCF fell 52.83% year-over-year to 34.55; the TTM figure through Jun 2026 stood at 7.83 (up 1.09% YoY), while the FY2025 annual figure was 8.83, up 13.2% from the prior year.
• EV to FCF came in at 34.55 for Q2 2026 at CRISPR Therapeutics AG, down from 19.59 in the prior quarter.
• In the past five years, EV to FCF ranged from a high of 293.35 in Q1 2023 to a low of 49.21 in Q3 2025.
• Average EV to FCF over 5 years is 5.62, with a median of 21.31 recorded in 2025.
• Year-over-year, EV to FCF plunged 240.89% in 2022 and surged 1775.67% in 2023.
• Over 5 years, EV to FCF stood at 11.51 in 2022, then slumped by 197.57% to 34.26 in 2023, then increased by 14.63% to 29.25 in 2024, then decreased by 12.14% to 32.8 in 2025, then declined by 5.34% to 34.55 in 2026.
• Per Business Quant data, the three most recent EV to FCF figures were 34.55 in Q2 2026, 19.59 in Q1 2026, and 32.8 in Q4 2025.